Hematology/oncology institutions, practices announce faculty promotions, additions
The following faculty promotions and additions and board elections have taken place at U.S. hematology/oncology practices and institutions:
- Vivek S. Kavadi, MD, FASTRO, has been named chief radiation oncologist for The US Oncology Network. Kavadi will be responsible for overseeing development of clinical strategies and best practices that advance delivery of innovative radiation therapies across the network. He also will lead new radiation oncology initiatives designed to help practices provide value-based care.
- At City of Hope, Charles Brenner, PhD, has joined as chair of the institution’s new department of diabetes and cancer metabolism. Brenner will focus on metabolic disturbances that underlie cancer, diabetes and their complications. He also will recruit other faculty members whose work relates to the relationship between cancer and diabetes.
Also, Glenn D. Steele Jr., MD, PhD, has been elected chair of City of Hope’s board of directors. Steele joined the board in January 2016, and he previously served as chair of the executive compensation and governance committee. His work has focused on cell biology of gastrointestinal cancer and precancer, as well as innovations in health care delivery and financing.
- Edward Chu, MD, MMS, has been named director of Albert Einstein Cancer Center. Chu also will serve as vice president for cancer medicine at Montefiore Medicine — which comprises Montefiore Health System and Albert Einstein College of Medicine — as well as professor of medicine and professor of molecular pharmacology at Albert Einstein College of Medicine.
- Raymond N. DuBois, MD, PhD, dean of Medical University of South Carolina’s College of Medicine, has been appointed director of MUSC Hollings Cancer Center. DuBois has led the institution’s College of Medicine since March 2016.
- Henry A. Pitt, MD, has been named chief of oncologic quality at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital. Pitt will provide oversight for the planning and execution of quality improvement, performance excellence, patient safety and satisfaction, infection control and outcomes reporting.
- Fox Chase Cancer Center announced several faculty appointments. These include, Elizabeth A. Bourne, DO, assistant professor in the division of hospitalist medicine; Gabriel Isaza, MD, assistant professor in the division of dermatology; Robert Brenchak, MD, assistant professor in the division of hospital medicine; Jason Alfred Castellanos, MD, MS, assistant professor in the academic clinician track in the division of general surgery; Maureen V. Hill, MD, clinical instructor in the department of surgical oncology; Christopher M.K.L. Yao, MD, FRCSC, assistant professor in the academic clinician track in the division of head and neck surgery; Jean M. Arlt, PhD, assistant professor in the division of psychiatry; Andrea S. Porpiglia, MD, MSc, assistant professor in the academic clinician track in the department of surgical oncology; Shazia K. Nakhoda, MD, who joined the hematology-lymphoma program within the department of hematology/oncology; Weier Li, MD, assistant professor in the department of diagnostic imaging; Jessica Karen Wong, MD, MEng, assistant professor in the department of radiation oncology; J. Nicholas Bodor, MD, PhD, MPH, who will serve in the thoracic oncology program within the department of hematology/oncology; and Brandon Bachert, MD, assistant professor in the department of diagnostic imaging.
- Roswell Park Comprehensive Cancer Center appointed three staff members within its department of gynecologic oncology to leadership roles. Peter Frederick, MD, FACOG, has been named clinical chief of gynecology; Emese Zsiros, MD, PhD, FACOG, has been named director of research; and Melissa Moffitt, MD, has been named fellowship program director.
Also, Eunice Wang, MD, has been named medical director of infusion services. Wang will oversee infusion services on the institution’s main campus, as well as at its satellite clinics.
- Janice M. Mehnert, MD, has been appointed associate director for clinical research at NYU Langone Health’s Perlmutter Cancer Center. Mehnert, recognized for her expertise in early phase therapeutics and treatment of skin malignancies, previously served as associate professor of medicine at Robert Wood Johnson Medical School and regional phase 1 clinical program director at Rutgers Cancer institute.
- Parker Institute for Cancer Immunotherapy appointed John Connolly, PhD, as its chief scientific officer. Connolly will work with the institute’s leadership team, center directors and scientific steering team to design and execute its overall research strategy. He also will identify and expand partnerships with biotechnology and pharmaceutical companies to support the institute’s research efforts.
- Patrick Hwu, MD, has been appointed president and CEO of Moffitt Cancer Center. Hwu, a tumor immunologist, currently serves as division head of cancer medicine at The University of Texas MD Anderson Cancer Center. He will join Moffitt on Nov. 10.
- John Fox, MD, has been appointed medical director for managed care at OneOncology, a national partnership of independent oncology practices. Fox will work with the partner practices to develop and maintain value-based contracts with commercial and public payers.
- Jae Jung, PhD, has been appointed chair of Cleveland Clinic Lerner Research Institute’s department of cancer biology. Jung will oversee the department’s work to improve understanding of the biological underpinnings of cancer, including disease manifestation and genetic or molecular pathways.